Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. ANTX.NASDAQ

AN2 Therapeutics Inc (ANTX NASDAQ) stock market data APIs

$2.65 -0.03(-1.1%) as of July 26, 2024
Price chart is built with Anychart

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize, or otherwise exploit certain compounds and products, including epetraborole, for the treatment, diagnosis, or prevention of all human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize certain compounds and products, including epetraborole, in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

AN2 Therapeutics Inc Financial Data Overview

2.68
2.65
-
2.68
2.59
1.91-22.22
78 749 K
29 829 K
0
-0.56
-0.12
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'ANTX',
Type: 'Common Stock',
Name: 'AN2 Therapeutics Inc',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG00QYLYBK4',
ISIN: NULL,
CUSIP: NULL,
CIK: '1880438',
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: '2022-03-25',
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: NULL,
IsDelisted: false,
}

AN2 Therapeutics Inc Fundamental Data is available in our Financial Data APIs

  • Net Revenue 0
  • EBITDA 0
  • Earnings Per Share -2.51
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get AN2 Therapeutics Inc Earnings via APIs

  • Latest Release 2024-05-08
  • EPS/Forecast -0.7575

Get AN2 Therapeutics Inc End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get AN2 Therapeutics Inc latest news via APIs

13 Best Falling Stocks To Buy Right Now

In this piece, we will take a look at the 13 best falling stocks to buy now. If you want to skip our coverage of the latest stock market news, then you can take a look at the 5 Best Falling Stocks To ...

AN2 Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

U.S. Enrollment Ongoing in EBO-301 Pivotal Phase 2/3 Clinical Trial of Epetraborole in Treatment-Refractory MAC Lung Disease; Plan to Include Japanese Patients in Trial Awarded Contract from NIAID Val...
  • AN2 THERAPEUTICS
  • EARNINGS RELEASES AND OPERATING RESULTS
  • INC
  • NASDAQ:ANTX
Do you have any questions?
support@eodhistoricaldata.com